Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows:

Q2 2024 Press Release: Thursday, August 1, 2024 at 7:30 a.m. ET
Q2 2024 Conference Call/Webcast: Thursday, August 1, 2024 at 8:45 a.m. ET
     

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

Staff

Recent Posts

Cell BioEngines Secures an Additional $2 Million in Funding From SOSV and the Empire State Development’s New York Ventures

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a New York, USA-based…

1 hour ago

The Alberta Cancer Foundation’s Enbridge Tour Alberta for Cancer Passes $100 Million Milestone in its 16th Year

Over $7.3 million raised this year alone for Albertans facing cancer in Alberta’s largest cycling…

1 hour ago

RaySearch to present the latest advances in RayStation, RayCare and RayIntelligence at AAPM 2024

RaySearch will showcase its latest software innovations at AAPM 2024 in Los Angeles, CA (USA),…

22 hours ago

Zscale Labs™ Unveils Groundbreaking Neuromorphic AI for Medical Imaging

Cutting-Edge Technology Enhances Chest X-Ray Classification for Superior Patient Outcomes DUBAI, UAE, July 19, 2024…

1 day ago

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic…

2 days ago

NuGen Receives Order for Repeat Demand in Mexico

Toronto, Ontario--(Newsfile Corp. - July 19, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

2 days ago